The requirements for speed and economy are climbing in the biopharma industry. Go/no go decisions are being made earlier, and products need to be brought to market faster and at a better price point. These needs translate into increasing pressure to quickly create processes that are cost-effective at manufacturing scale. Gains in protein productivity can cumulatively make a real positive impact on your process economy.
When evaluating media with the goal of increasing titers, it is important to ensure that protein quality is not negatively impacted. So how can this process improvement be performed reliably? It makes sense to use a Design of Experiment (DoE) and empirical approach. Here is an example of how to do it.